Literature DB >> 33293697

Speech and language phenotype in Phelan-McDermid (22q13.3) syndrome.

Amanda Brignell1,2, Conway Gu2, Alison Holm3, Bronwyn Carrigg4, Daisy A Sheppard1,2, David J Amor1,2, Angela T Morgan5,6.   

Abstract

Communication difficulties are a core feature of Phelan-McDermid syndrome (PMS). However, a specific speech and language phenotype has not been delineated, preventing prognostic counselling and development of targeted therapies. We examined speech, language, social and functional communication abilities in 21 individuals with PMS (with SHANK3 involvement), using standardised assessments. Mean age was 9.7 years (SD 4.1) and 57% were female. Deletion size ranged from 41 kb to 8.3 Mb. Nine participants (45%) were non-verbal. Four (19%) had greater verbal ability, speaking in at least 4-5 word sentences, but with speech sound errors. Standard scores for receptive and expressive language were low (typically >3 SD below the mean). Language age equivalency was 13-16 months on average (range 2-53 months). There was a significant association between deletion size and the ability to use phrases. Participants with smaller deletion sizes were more likely to be able to use phrases (odds ratio: 0.36, 95% CI: 0.14-0.95, p = 0.040). Adaptive behaviour (life skills) was low in all areas (>2 SD below mean). Scores in communication were markedly lower than for daily living (p = 0.008) and socialisation (p < 0.001). A common linguistic profile was characterised by severe impairment across receptive, expressive and social language domains. Yet data indicated greater communicative intent than appeared to be capitalised by current therapies. Early implementation of augmentative (e.g. computer-assisted) modes of communication, alongside promotion of oral language, is essential to harness this intent, accelerate language development and reduce frustration. Future trials should examine the added benefit of targeted speech motor interventions in those with greater verbal capacity.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33293697      PMCID: PMC8115660          DOI: 10.1038/s41431-020-00761-1

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  3 in total

1.  The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome).

Authors:  K Phelan; H E McDermid
Journal:  Mol Syndromol       Date:  2011-11-22

Review 2.  Measuring behavioral phenotypes: provocations from the "new genetics".

Authors:  E M Dykens
Journal:  Am J Ment Retard       Date:  1995-03

3.  Clinical, cytogenetic, and molecular characterization of seven patients with deletions of chromosome 22q13.3.

Authors:  N J Nesslinger; J L Gorski; T W Kurczynski; S K Shapira; J Siegel-Bartelt; J P Dumanski; R F Cullen; B N French; H E McDermid
Journal:  Am J Hum Genet       Date:  1994-03       Impact factor: 11.025

  3 in total
  6 in total

1.  What's new in EJHG in April.

Authors:  Alisdair McNeill
Journal:  Eur J Hum Genet       Date:  2021-04       Impact factor: 5.351

2.  Variability in Phelan-McDermid Syndrome in a Cohort of 210 Individuals.

Authors:  Julián Nevado; Sixto García-Miñaúr; María Palomares-Bralo; Elena Vallespín; Encarna Guillén-Navarro; Jordi Rosell; Cristina Bel-Fenellós; María Ángeles Mori; Montserrat Milá; Miguel Del Campo; Pilar Barrúz; Fernando Santos-Simarro; Gabriela Obregón; Carmen Orellana; Harry Pachajoa; Jair Antonio Tenorio; Enrique Galán; Juan C Cigudosa; Angélica Moresco; César Saleme; Silvia Castillo; Elisabeth Gabau; Luis Pérez-Jurado; Ana Barcia; Maria Soledad Martín; Elena Mansilla; Isabel Vallcorba; Pedro García-Murillo; Franco Cammarata-Scalisi; Natálya Gonçalves Pereira; Raquel Blanco-Lago; Mercedes Serrano; Juan Dario Ortigoza-Escobar; Blanca Gener; Verónica Adriana Seidel; Pilar Tirado; Pablo Lapunzina
Journal:  Front Genet       Date:  2022-04-12       Impact factor: 4.772

3.  Sensory processing and adaptive behavior in Phelan-McDermid syndrome: a cross-sectional study.

Authors:  Sergio Serrada-Tejeda; María-Luz Cuadrado; Rosa Mª Martínez-Piédrola; Nuria Máximo-Bocanegra; Patricia Sánchez-Herrera-Baeza; Lucía Rocío Camacho-Montaño; Marta Pérez-de-Heredia-Torres
Journal:  Eur J Pediatr       Date:  2022-07-15       Impact factor: 3.860

4.  Phelan-McDermid Syndrome in Pediatric Patients With Novel Mutations: Genetic and Phenotypic Analyses.

Authors:  Liang Chen; Zhi-Ye Yao; Xiangtao Wu; Shao-Ru He; Yu-Mei Liu; Xue-Yan Wang; De-Zhi Cao; Xing-Kun Yang; Jian-Bo Zhao; Zi Ren; Hong Li; Zheng Pei; Hong-Ke Ding; Zhi-Chun Feng
Journal:  Front Pediatr       Date:  2022-08-23       Impact factor: 3.569

5.  Social and Family Challenges of Having a Child Diagnosed with Phelan-McDermid Syndrome: A Qualitative Study of Parents' Experiences.

Authors:  Cristina García-Bravo; Domingo Palacios-Ceña; Sara García-Bravo; Jorge Pérez-Corrales; Marta Pérez-de-Heredia-Torres; Rosa Mª Martínez-Piédrola
Journal:  Int J Environ Res Public Health       Date:  2022-08-24       Impact factor: 4.614

6.  SHANK3 Genotype Mediates Speech and Language Phenotypes in a Nonclinical Population.

Authors:  Christina Manning; Peter L Hurd; Silven Read; Bernard Crespi
Journal:  Autism Res Treat       Date:  2021-06-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.